INDP

Indaptus Therapeutics, Inc.

1.95 USD
-0.25 (-11.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Indaptus Therapeutics, Inc. stock is up 18.18% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 March’s closed higher than February.

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.